SCHEDULE 13G/A: Eventide Asset Management and Affiliates Disclose 3.73% Stake in Lexeo Therapeutics
Beneficial Ownership Disclosure
Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, have disclosed a combined beneficial ownership of 3.73% in Lexeo Therapeutics, Inc. common stock as of December 31, 2024.
Summary
- Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Lexeo Therapeutics, Inc.
- As of December 31, 2024, the reporting persons collectively beneficially own 1,234,834 shares of Lexeo Therapeutics, Inc. Common Stock.
- This ownership represents 3.73% of the total outstanding shares of the class.
- Eventide Asset Management, LLC holds sole voting and dispositive power over all 1,234,834 shares.
- Finny Kuruvilla, M.D., Ph.D. and Robin C. John each hold shared voting and dispositive power over the same 1,234,834 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of ownership and does not contain performance or forward-looking statements.
Positives
- The beneficial ownership is below the 5% threshold, indicating it is not intended to influence or change control of the issuer.
- The filing confirms the shares were acquired and are held in the ordinary course of business.
Negatives
- No negative information regarding the issuer's performance or outlook is contained within this ownership disclosure.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor and does not provide specific industry context or trends.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event requiring the filing of this statement (beneficial ownership calculation date). |
| 02/10/2025 | Date of signing and filing of the Schedule 13G Amendment No. 3. |
Keywords
Lexeo Therapeutics, Eventide Asset Management, Schedule 13G, beneficial ownership, common stock, investment filing, SEC filing, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.